The use of the enzyme immunoassay (EIA) in screening for Chlamydia trachomatis in genital specimens is widely accepted. For most EIA kits, the signal strength or absorbance value is usually proportional to the amount of antigen present in the specimen; thus, a range of absorbance values may be encountered with each batch of specimens tested. The positive threshold provides a reference for assessing whether each sample's absorbance corresponds to a reactive result. This value is not absolute and incorporates statistical elements in its derivation, consequently both false positive and negative results are likely.
To improve the specificity ofthe EIA without sacrificing sensitivity, additional verification procedures for EIA reactive samples have employed blocking assays,"2 preparation of an additional slide for direct immunofluorescence assay (DFA) testing,3 and DFA on the cytocentrifuged culture transport medium or EIA specimen buffer.45 In these studies the numbers of samples examined were small and/or the verification procedures were performed only on those found to be reactive or discrepant.
From previous evaluations of this and other kits (American Society of Microbiology Abstracts, 1989, and unpublished observations), we noted that when the DFA was performed on the sample buffer ofspecimens with absorbance values below the positive threshold, a number contained elementary bodies. As the greatest numbers seemed to occur in the 30% adjunct zone, we included this range in an analysis of EIA reactive samples found during routine testing.
Methods
Endocervical and urethral swabs from women, or urethral swabs from men attending the Sexually Transmitted Diseases (STD) Clinic, Family Planning Clinic and Sexual Health Clinics, Calgary, were evaluated for this study. When possible, a paired set of urethral and cervical swabs was obtained from female patients attending the STD Clinic.
Patients from the STD Clinic were considered to have a higher prevalence (high risk group) than the other clinics (medium risk group) and the data were analysed by each specimen's clinic of origin.
The Syva MicroTrak EIA (Syva, Palo Alto, California, USA) was used to screen the samples and the assay was performed as stipulated by the manufacturer. The positive threshold was determined according to kit protocol. An adjunct category included those samples with absorbance values in a range from 30% below to the positive threshold. All reactive samples were verified by a confirmatory assay as described later. In addition, samples with absorbance values in the adjunct range, and both urethral and cervical swabs of a paired set when one of these gave an absorbance in the ranges described previously, were also verified.
For confirmatory testing, specimen buffer (400 p1) was centrifuged at 10 000 x g for 10 minutes in a microfuge. The When those samples with absorbance values within the adjunct range were included, an additional 94 swabs from the high risk group were also tested by DFA (20 cervical swabs, 30 female urethral swabs, and 44 male urethral samples). After DFA testing, 21 of 94 (22 3%) swabs from 21 patients also contained elementary bodies (12 male urethral, five female urethral, and four cervical swabs). These 21 additional patients, nine women and 12 men, represented 5-6% (21 of 374) of the total number ofpatients with DFA confirmed specimens. The nine women with sample absorbance values in the 30% adjunct range all had paired sets of samples collected. For two women, the alternate swab of the pair was negative on both EIA and DFA, whereas for the remaining seven, the alternate swab of the pair was EIA reactive and DFA positive. Table 1 shows the results of paired urethral and cervical swabs from 158 women from the high risk group when one of the pair of samples taken was EIA reactive and DFA positive. In 53% of these female patients both swabs were EIA reactive and DFA positive, and 33% had only one of the pair as a confirmed reactive. A number of other combinations were found and comprised about 13% of the total. There were four women from whom one swab was EIA reactive but DFA negative.
In the medium risk group 93-7% (236 of 252) of EIA reactive samples were confirmed as true positives (collected from 236 patients). Within the 30% adjunct range, 35 additional samples required verification and 22 (62.9%) of these (from 22 women) were confirmed as positive by DFA. This represented 9 3% of the total number of patients with confirmed, reactive swabs (22 of 236) compared with 5-6% from the high risk group.
With the MicroTrak DFA as the reference, the sensitivity of the EIA test was determined to be 95-7 and 91-5% for the high and medium risk groups, respectively. Similarly, specificities of 92-3 and 93-6%, respectively, were determined based on the kit criteria. Prevalences of 8-0 and 4-6% were calculated for the high and medium risk groups, respectively, based on the laboratory data (after correction for multiple swabs from individual patients).
An 
Discussion
In this study the results from a large number of specimens revealed the range of confirmed and unconfirmed EIA reactive samples that would be encountered in a diagnostic setting. Analysis by specimen origin and site showed that the sensitivity and specificity were similar between the two risk groups of varying disease prevalence, indicating that the kit performed equally in both. Furthermore, the lack of a statistical difference between the DFA confirmed and unconfirmed specimens provided additional support. Similar sensitivities have been found in other studies.910 Although we noted a lower specificity in our study compared with another,9 this may be explained by the DFA being performed on all our reactive specimens rather than on selected samples.
A number of studies'-3 have applied the DFA to verify EIA reactive results from alternative kits to the one we used. Schwebke et al' noted that the specificity could be improved to almost 100% by verifying swabs with absorbance quotients over a wide range both above and below the positive threshold. A consequence of this wide quotient range was that at least 25% of the samples required testing by DFA compared with 14% in our study, of which one third were confirmed as positive. In the other studies,'2 DFA testing was only performed when discrepancies were observed between the various assays.
From other studies,"1 12 where an alternative EIA kit to the one here was used, it was noted that a proportion of specimens with reactive absorbance values were not confirmed on DFA testing, and that this proportion declined as the absorbance values increased. We applied a stringent 99% confidence level to assess the reliability of the EIA results for the different quotient categories. From our results, an average of about 50% of EIA reactive tests from both groups could not be equivocally relied upon until this quotient exceeded 4-0. Thus, specimens with absorbance values equivalent to a quotient of less than this value should be verified by an alternative procedure. Detection of true positive results among specimens with absorbances in the adjunct range is a potential benefit of this scheme, although it does require extra technical time in order to verify the additional samples, many of which are likely to be negative. However, the numbers in our study were relatively low (129 swabs) in relation to the total numbers of specimens tested: this justifies the time spent on the verification procedure.
As with the EIA, the DFA verification test is also prone to false negative results. In our study there were four of 89 (4-5%) samples from paired sets of cervical and urethral swabs when one was both EIA reactive and DFA positive and the other swab although EIA reactive, was not confirmed by the DFA. By applying this percentage to those reactive specimens unconfirmed by DFA it is likely that an additional three patients from both risk groups would have been reported as falsely negative.
In summary, we accept that the screening test will not identify all positive samples, although the 30% adjunct zone provides a compromise which detects additional patients without verification of an unduly large number of specimens. Furthermore, although all EIA reactive samples above the recommended cut off value should be verified in order to identify potential false positive results, from a practical standpoint it would be appropriate to confirm only those with a quotient of between 1 and 4 with respect to the positive cut off value.
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